ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without ...
CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with ...
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...
Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...
After partnering with Depend last year following his bladder cancer surgery, Colorado head coach Deion Sanders brought his ...
Theralase Technologies (TSXV:TLT) has shown in pre-clinical trials that its flagship Rutherrin, when activated by X-Ray, is ...
Stocktwits on MSN
IBRX stock rises premarket as founder flags early Anktiva immune data — Macau nod fuels bull case
Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study. ・Anktiva was also ...
Hello, and welcome to the Protara Therapeutics ASCO GU Update Call. [Operator Instructions] As a reminder, this conference call is being recorded. If you have any objections, please disconnect at this ...
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results